Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548490 | 0.82 | GRIA3 (0.56) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL562597 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL2733233 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL30356124 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL1708565 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL9731669 | 0.79 | ADORA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL8237246 | 0.76 | GRIA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL1420530 | 0.76 | ADORA3 (0.57) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL12201007 | 0.76 | ADORA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL13689278 | 0.76 | GAA (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125356-A1 | TREATMENT OF LEISHMANIASIS | THE UNIV OF DURHAM (GB) | 2026-05-07 | — | — | US | disclosed |
| EP-4605086-A1 | TREATMENT OF LEISHMANIASIS | The University of Durham (GB) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024084186-A1 | TREATMENT OF LEISHMANIASIS | THE UNIVERSITY OF DURHAM (GB) | 2024-04-25 | — | — | WO | disclosed |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | VENTANA MED SYST INC (US) | 2018-05-03 | — | — | US | disclosed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2154970-B1 | DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | RESPIRERX PHARMACEUTICALS INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9719986-B2 | Haptens, hapten conjugates, compositions thereof preparation and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9492440-B2 | Bicyclic amides for enhancing glutamatergic synaptic responses | RESPIRERX PHARMACEUTICALS INC (US) | 2016-11-15 | — | — | US | disclosed |
| US-6344451-B1 | DIABETES INSIPIDUS, NOCTURNAL ENURESIS, NOCTURIA, URINARY INCONTINENCE, BLEEDING AND COAGULATION DISORDERS, OR TEMPORARY DELAY OF URINATION | AMERICAN HOME PRODUCTS | 2002-02-05 | — | — | US | disclosed |
| EP-1149104-A2 | PYRROLOBENZODIAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-31 | — | — | EP | disclosed |
| EP-1149097-A2 | PYRIDOBENZODIAZEPINE AND PYRIDOBENZOXAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-31 | — | — | EP | disclosed |
| WO-2000046225-A2 | PYRIDOBENZODIAZEPINE AND PYRIDOBENZOXAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| WO-2000046228-A2 | PYRROLOBENZODIAZEPINE CARBOXYAMIDE VASOPRESSIN AGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-10 | — | — | WO | disclosed |
| EP-0719263-B1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY | SMITHKLINE BEECHAM LAB (FR) | 1998-07-15 | — | — | EP | disclosed |
| WO-1996027595-A1 | HETEROCYCLYCARBOXAMIDES AND OTHER COMPOUNDS FOR THE TREATMENT OF THE CARDIAC ARRHYTHMIAS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-09-12 | — | — | WO | disclosed |
| EP-0719263-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007903-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-03-23 | — | — | WO | disclosed |
| US-5112824-A | Benzofurazan compounds | MERCK & CO., INC. (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180120306-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | CRBN, AHR, RORB | GRIA3 388/4885GRIA4 243/4885ENPP2 3345/4885 |
| US-20260125356-A1 | TREATMENT OF LEISHMANIASIS | NR1H2, NR1H3, MSR1 | GRIA3 702/4885GRIA4 418/4885ENPP2 1310/4885 |
| US-11092594-B2 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, AHR, RORB | GRIA3 388/4885GRIA4 243/4885ENPP2 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.